The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma

Click to increase image sizeClick to decrease image size

Additional information

Notes on contributors

Robert A. Figlin

Robert A. Figlin, MD, FACP, is Steven Spielberg Family Chair in Hematology Oncology; professor of medicine and biomedical sciences; director, Division of Hematology Oncology; deputy director, Integrated Oncology Service Line; deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars‐Sinai Medical Center, New York, N.Y. Jocelyn Mohs, PharmD, BCOP, is pharmacy supervisor, Infusion Clinic Pharmacy, Sanford Roger Maris Cancer Center, Fargo, N.D. Laura S. Wood, RN, MSN, OCN, is renal cancer research coordinator, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Jocelyn Mohs

Robert A. Figlin, MD, FACP, is Steven Spielberg Family Chair in Hematology Oncology; professor of medicine and biomedical sciences; director, Division of Hematology Oncology; deputy director, Integrated Oncology Service Line; deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars‐Sinai Medical Center, New York, N.Y. Jocelyn Mohs, PharmD, BCOP, is pharmacy supervisor, Infusion Clinic Pharmacy, Sanford Roger Maris Cancer Center, Fargo, N.D. Laura S. Wood, RN, MSN, OCN, is renal cancer research coordinator, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Laura S. Wood

Robert A. Figlin, MD, FACP, is Steven Spielberg Family Chair in Hematology Oncology; professor of medicine and biomedical sciences; director, Division of Hematology Oncology; deputy director, Integrated Oncology Service Line; deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars‐Sinai Medical Center, New York, N.Y. Jocelyn Mohs, PharmD, BCOP, is pharmacy supervisor, Infusion Clinic Pharmacy, Sanford Roger Maris Cancer Center, Fargo, N.D. Laura S. Wood, RN, MSN, OCN, is renal cancer research coordinator, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.